ClinicalTrials.gg
RecruitingNCT06715761Updated Dec 9, 2024

Effectiveness of Manual and Instrumental Myofascial Release in Chronic Low Back Pain and the Posture of Practitioners CrossFit®

An interventional study of Myofascial release and Cupping therapy in Low Back Pain, sponsored by Gabriela Souza de Vasconcelos. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Gabriela Souza de Vasconcelos · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Low Back Pain with a site in Brazil — 10 open to participants now, 12 under way, none of them phase 3. Low Back Pain · Brazil.

Planned enrollment
78th of 122
51 · median 66
Started
2024
with 2 others
No phase
101 of 125
9 open now
Primary completion
2025-07
later than 4 of 11 live
Registered
122nd of 125
by date

Among the 125 studies in Low Back Pain with a site in Brazil, this one is the 78th largest by planned enrollment of the 122 interventional ones that give a count, is one of 3 that started in 2024, is one of 101 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 122nd registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

10 of the 125 studies in Low Back Pain with a site in Brazil are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Low Back Pain with a site in Brazil, or all of them as a file.
02

Study summary

Background: Chronic low back pain (LBP) can lead to major functional disabilities and force people to take time off work, sports or leisure activities. Regular physical exercise is an important ally in reducing the risk factors for most diseases, and CrossFit® is one of the modalities that has been gaining momentum when choosing an exercise. However, the intensity recommended in training can collaborate with the development of musculoskeletal problems such as pain and postural changes, interfering with the development of the practice, with low back pain being one of the most common disorders in these practitioners, especially caused by mechanical stress. Considering that CrossFit® practitioners have already incorporated physical exercise into their routine, passive techniques such as myofascial release (ML) have been discussed as a form of treatment for LBP. For this reason, this study was designed to verify the efficacy of ML in the LBP of CrossFit® practitioners, comprising two techniques, one manual and one instrumental, and to see if the outcome of the LBP alters the posture of the spine.

This is a randomised controlled clinical that will be conducted in a CrossFit® box in the city of Goiânia-GO, Brazil. At least 51 people will take part who have been doing CrossFit® for at least 3 months, who have LBP, are aged between 18-59 and are not undergoing any other treatment for low back pain. There will be two experimental groups, one that will receive manual MR and the other, cupping therapy, as well as a control group that will not receive any technique. The sessions will take place twice a week for 8 weeks. The primary outcome will be low back pain intensity, assessed at baseline, weekly and after 8 weeks, and the secondary outcomes, which will be postural deviations, spinal mobility and history of musculoskeletal pain, assessed at baseline and at the end of 8 weeks. There will be no blinding between therapist and participants.

Discussion: This study will investigate whether MR is effective in relation to LBP, given that some results have already shown positive responses in acute conditions, while also verifying the repercussions on the postural aspect. The results could provide additional knowledge about the best technique to use and, having applicability to our outcomes, will favour and simplify treatment, helping professionals to make clinical decisions.

03

Conditions studied

  • Low Back Pain

Browse trials for

Keywords

  • Low back pain
  • Myofascial release
  • CrossFit
  • Posture
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • men and women aged between 18 and 59 years;
  • presence of low back pain for at least 12 weeks;
  • have started regular CrossFit® activity at least 3 months ago.

Exclusion criteria

Exclusion Criteria:

  • perform other physical activity than CrossFit®;
  • continuous use of painkillers;
  • previous pathologies or spinal surgery;
  • amputations;
  • haematological disorders;
  • fibromyalgia;
  • or skin lesions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    Myofascial release group (MRG)

    Other: Myofascial release

  • Active comparator
    Cupping therapy group (CTG)

    Other: Cupping therapy

  • No intervention
    Control group (CG)

    Wait-and-see

Interventions

  • OtherMyofascial release

    The sequence of myofascial release is as follows: 30 seconds of contact between the therapist's hands and the entire region of the participant's spine, sliding with medium pressure in a caudocranial direction; palpation of the erector spinae, quadratus lumborum, gluteus and piriformis muscles bilaterally, to identify trigger points, marking each point of tension with a dermographic pencil for subsequent manipulation; 3 cycles of bilateral paravertebral release, by sustained pressure with crossed hands, until the restrictive tissue barrier is found, for 60 seconds; 90 seconds of the vertical rolling technique (superficial elevation of the skin and mobilisation of the tissue with the tips of all the fingers) on the bilateral paravertebrals and, at the end, sliding along the entire length of the bilateral multifidus, with the fingers flexed, using the bony prominence between the proximal and middle phalanges as contact with the skin, in a caudocranial direction and returning craniocaudal.

  • OtherCupping therapy

    The acrylic cups (DongBang®) will be placed on the meridional points, as Traditional Chinese Medicine calls them, 1 cup in the central region of each popliteal fossa, the so-called B40 or Wei Zhong point, 6 cups in the region of the quadratus lumborum muscles, more specifically on the BL23 or Shenshu points (approximately 5 centimetres lateral to the edge of the L2 spinous process), BL24 or Qihaishu (approximately 5 centimetres lateral to the edge of the spinous process of L3) and BL25 or Dachangshu (approximately 5 centimetres lateral to the edge of the spinous process of L4) bilaterally, as well as a cup on a single point of the participant's choice, where they report the most lower back pain (ashi point). The cups will be attached to the skin using a gun, applying two suction pressures, and the participant will be asked to signal whether the pressure is strong or weak. The cups will remain attached for 12 minutes on the B40 meridian and 15 minutes on the other meridians. If a cup lo

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Pain intensity, related to chronic low back pain, will be measured using the Visual Analogue Scale (VAS), where 0 represents "no pain" and 10 represents "the worst pain possible". Participants will indicate their usual pain.

    Time frame: Baseline, once a week throughout the intervention period (at the beginning of each week) and post intervention (8 weeks)

Secondary outcomes

  1. Spinal postural deviations

    Spinal postural deviations will be measured using a flexible lead ruler called a Flexicurve (Trident®). Initially, the anatomical points of the spinous processes of the C7, T1, T6, T12, L1, L4, L5, S1 and S2 vertebrae will be marked on the participant's skin with a white dermatographic pencil (Hintz®). The flexicurve will then be moulded and the anatomical reference points will also be marked on the body of the ruler. After this, the ruler will be positioned in the centre of the page of a 420mmX549mm piece of graph paper (Tracing Pad®), where its shape will be reproduced. For the analysis, the drawings with the shapes of the curvatures of the spine will be photographed and entered into the Dynamic Posture software.

    Time frame: Baseline and post intervention (8 weeks)

  2. Spine mobility

    Spinal mobility will be analysed using Finger Tip Test. For the Finger Tip Test, the participant will stand and then be instructed to flex their trunk as if they wanted to touch their hands to the floor. The distance between the distal phalanx of the 3rd finger of the hand and the floor will be measured with a tape measure (Incoterm®).

    Time frame: Baseline and post intervention (8 weeks)

  3. History of musculoskeletal pain

    A history of musculoskeletal pain will be taken using the Questionnaire For Evaluation Of Musculoskeletal Pain In Exercise Practitioners (Q-ADOM). The questionnaire is used to screen for musculoskeletal pain in exercise practitioners and, although it has domains that can cover any type of pain, the participant will be instructed to answer the visual analogue scale (item 1) and the other items, only considering the intensity of the pain and the symptoms related to their chronic low back pain.

    Time frame: Baseline and post intervention (8 weeks)

07

Study locations

1 of 1 sites recruiting
  • Federal University of Goias
    Goiânia, Goias 74690-900, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2025, 8 months after the start.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 8 months is below that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2024
First posted
Dec 4, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Jul 30, 2025
CompletionEst.
Jul 30, 2025
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06715761
Lead sponsor
Gabriela Souza de Vasconcelos
Responsible party
Gabriela Souza de Vasconcelos (Professor, Universidade Federal de Goias) — Sponsor-investigator
First posted
Dec 4, 2024
Start date
Nov 1, 2024
Primary completion
Jul 30, 2025 (estimated)
Completion
Jul 30, 2025 (estimated)
Last update
Dec 9, 2024

Study contacts

Gabriela de Vasconcelos, PhD
Contact
gabriela_vasconcelos@ufg.br
+5551995372276

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion